How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects

Cristina Vilaplana; Pere Joan Cardona

doi:10.1016/j.arbres.2018.11.002

How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects

Cristina Vilaplana, Pere Joan Cardona

Department of Genetics and Microbiology

Research output: Contribution to journal › Review article › Research › peer-review

2 Citations (Scopus)

Abstract

© 2018 SEPAR Tuberculosis still is a major public health problem worldwide, and vaccines may play a major role in its eradication. However, despite 20 years of intensive research, we still do not have a better vaccine than the Bacille Calmette-Guérin vaccine, which has been used since 1921 but exhibits only limited efficacy in the field. This effort has not, however, been entirely in vain as our understanding of TB vaccinology has been substantially expanded and there are currently 17 vaccine candidates in clinical development and several more in preclinical trials. This manuscript reviews the most important recent advances, concerns raised and future prospects in the TB vaccinology field.

Original language	English
Pages (from-to)	373-377
Journal	Archivos de Bronconeumologia
Volume	55
Issue number	7
DOIs	https://doi.org/10.1016/j.arbres.2018.11.002
Publication status	Published - 1 Jul 2019

Keywords

Bacille Calmette-Guérin
Clinical trials
Tuberculosis
Vaccine

Access to Document

10.1016/j.arbres.2018.11.002

Fingerprint Dive into the research topics of 'How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects'. Together they form a unique fingerprint.

Cite this

@article{3d8774eaf4c44255a5f90dc786876945,

title = "How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects",

abstract = "{\textcopyright} 2018 SEPAR Tuberculosis still is a major public health problem worldwide, and vaccines may play a major role in its eradication. However, despite 20 years of intensive research, we still do not have a better vaccine than the Bacille Calmette-Gu{\'e}rin vaccine, which has been used since 1921 but exhibits only limited efficacy in the field. This effort has not, however, been entirely in vain as our understanding of TB vaccinology has been substantially expanded and there are currently 17 vaccine candidates in clinical development and several more in preclinical trials. This manuscript reviews the most important recent advances, concerns raised and future prospects in the TB vaccinology field.",

keywords = "Bacille Calmette-Gu{\'e}rin, Clinical trials, Tuberculosis, Vaccine",

author = "Cristina Vilaplana and Cardona, {Pere Joan}",

year = "2019",

month = jul,

day = "1",

doi = "10.1016/j.arbres.2018.11.002",

language = "English",

volume = "55",

pages = "373--377",

number = "7",

}

TY - JOUR

T1 - How Far Are we Away From an Improved Vaccine For Tuberculosis? Current Efforts and Future Prospects

AU - Vilaplana, Cristina

AU - Cardona, Pere Joan

PY - 2019/7/1

Y1 - 2019/7/1

N2 - © 2018 SEPAR Tuberculosis still is a major public health problem worldwide, and vaccines may play a major role in its eradication. However, despite 20 years of intensive research, we still do not have a better vaccine than the Bacille Calmette-Guérin vaccine, which has been used since 1921 but exhibits only limited efficacy in the field. This effort has not, however, been entirely in vain as our understanding of TB vaccinology has been substantially expanded and there are currently 17 vaccine candidates in clinical development and several more in preclinical trials. This manuscript reviews the most important recent advances, concerns raised and future prospects in the TB vaccinology field.

AB - © 2018 SEPAR Tuberculosis still is a major public health problem worldwide, and vaccines may play a major role in its eradication. However, despite 20 years of intensive research, we still do not have a better vaccine than the Bacille Calmette-Guérin vaccine, which has been used since 1921 but exhibits only limited efficacy in the field. This effort has not, however, been entirely in vain as our understanding of TB vaccinology has been substantially expanded and there are currently 17 vaccine candidates in clinical development and several more in preclinical trials. This manuscript reviews the most important recent advances, concerns raised and future prospects in the TB vaccinology field.

KW - Bacille Calmette-Guérin

KW - Clinical trials

KW - Tuberculosis

KW - Vaccine

U2 - 10.1016/j.arbres.2018.11.002

DO - 10.1016/j.arbres.2018.11.002

M3 - Review article

C2 - 30594319

VL - 55

SP - 373

EP - 377

IS - 7

ER -